Amgen's denosumab succeeds in key osteoporosis trial
This article was originally published in Scrip
Executive Summary
Amgen's novel drug denosumab prevents fractures, as well as increasing bone mineral density, in postmenopausal women with osteoporosis, top-line results from a 7,800-patient pivotal Phase III study suggest.